Creative Touch Permanent Makeup and Aesthetics

Paradoxical adipose hyperplasia (PAH) is a recognised complication of cryolipolysis in which the cold stimulus produces the opposite of its intended effect – instead of triggering adipocyte apoptosis and volume reduction, it stimulates a proliferative response that increases the volume of adipose tissue in the treated area. The enlargement typically becomes visible as a firm, well-demarcated mass 2–6 months after treatment, and is visually and palpably distinct from the surrounding tissue. ^[2]

PAH does not resolve spontaneously. Once established, surgical correction – typically liposuction, or abdominoplasty in severe cases – is required. Early identification and prompt referral for surgical assessment is the appropriate clinical response when PAH is suspected. ^[2]

The exact mechanism is not established. Current hypotheses include paradoxical proliferation of preadipocytes stimulated by the cold injury, disruption of sympathetic nerve signalling in adipose tissue, cold-induced hypoxia triggering fibrotic and hyperplastic responses, and fibrous septal thickening creating a compartmental expansion effect. No single mechanism has been confirmed in primary research. ^[3]

Incidence

The originally reported incidence of approximately 0.0051% (1 in 20,000 treatment cycles) is now considered a significant underestimate, reflecting incomplete adverse event reporting in early post-market data rather than true population incidence. More recent multicenter evaluation data report incidence figures below 1 in 2,000, with some case series reporting rates up to 0.41% depending on device generation, applicator type, anatomical site, and patient characteristics. The most current published incidence analysis places the figure between these bounds. The honest clinical position is that true incidence lies between approximately 1 in 2,000 and 1 in 250 – rare but not negligible. ^[1]

Risk Factors

Male sex is the most consistently identified risk factor across published case series. Certain anatomical sites and older vacuum-suction applicator designs have been associated with higher rates in some reports. No single pre-treatment factor reliably predicts PAH in an individual. ^[2]

Pre-Treatment Disclosure

Pre-treatment disclosure of PAH risk is a clinical and ethical requirement. Clients should be informed that:

• PAH is a recognised, rare complication in which treated fat increases in volume rather than decreasing ^[2]
• It does not resolve without surgical intervention ^[2]
• Surgical correction is required if it occurs
• Male sex is an identified risk factor ^[3]